Outcome
|
Atorvastatin
40mg Users
(N= 475)
n (%)
|
Atorvastatin 80mg Users
(N= 151)
n (%)
|
Hazard Ratio
95% CI
|
P-value
|
Adjusted Hazard Ratio
95% CI
|
P-value
|
Primary endpoint at 1 month
|
4 (0.8)
|
2 (1.3)
|
0.60
(0.10-3.30)
|
0.551
|
0.59
(0.04-8.13)
|
0.690
|
CVD-associated death, non-fatal ACS, and non-fatal stroke
|
|
|
|
|
|
|
Primary endpoint at 12 months
|
15 (3.2)
|
6 (4.0)
|
0.58
(0.22-1.50)
|
0.243
|
0.57
(0.18-1.80)
|
0.340
|
CVD-associated death, non-fatal ACS, and non-fatal stroke
|
|
|
|
|
|
|
CVD: cardiovascular disease; ACS: acute coronary
syndrome |
CVD: cardiovascular disease; ACS: acute
coronary syndrome |
CVD: cardiovascular disease; ACS:
acute coronary syndrome |
CVD: cardiovascular disease;
ACS: acute coronary syndrome |
CVD: cardiovascular
disease; ACS: acute coronary syndrome |
CVD:
cardiovascular disease; ACS: acute coronary syndrome |
CVD: cardiovascular disease; ACS: acute coronary
syndrome |